Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter April 11, 2013

The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome

  • Wiebke Schaarschmidt EMAIL logo , Sarosh Rana and Holger Stepan

Abstract

Aims: Preeclampsia (PE) is considered a uniformly progressive disease, however, it shows a different pattern of clinical progression in patients with early (<34 weeks) or late (≥34 weeks) onset of the disease. Angiogenic factors such as soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF) are closely related to the clinical course of PE. We evaluated sFlt-1 and PlGF levels in the clinical course of PE in women admitted with a diagnosis of PE at different gestational ages.

Methods: This retrospective study included 34 patients with PE, of which 11 patients had HELLP syndrome (over a period of 3 years). Serial measurements of sFlt-1 and PlGF were completed from admission until delivery. Values are presented as mean±standard deviation.

Results: Mean gestational age of admission among women with early onset PE was significantly lower, at 29±3 weeks compared to 37±1 weeks among patients with late onset disease. Mean prolongation of pregnancy was 6 days, which was similar within the two groups. Compared to women with late onset PE, women with early-onset PE had a greater increase in sFlt-1 (11% vs. 3% per day, P<0.05), greater decrease in PlGF levels (21% vs. 10% per day, P=0.30), resulting in a much higher increase in sFlt-1/PlGF ratio (23% vs. 8% per day, P<0.05). Patients with HELLP syndrome showed comparable progression patterns.

Conclusion: In a similar way to the progressively worsening clinical course observed in women with early onset PE, there were changes in the angiogenic profile that leads to a more anti-angiogenic state in these women with each passing day. These findings may have implications in identification of the women for appropriate patient management and possible future therapies based on the reduction of sFlt-1 levels.


Corresponding author: Wiebke Schaarschmidt, MD, Department of Obstetrics, University Hospital of Leipzig, Liebigstr. 20a, 04103 Leipzig, Germany, Tel.: +49-341-9723595, Fax: +49-341-9723599

S. Rana is supported NID/NICHD (K08HD068398-01A1).

Conflict of interest statement:

H. Stepan has received consultancy payments from Roche regarding advice on clinical trial design.

References

[1] ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 2002;99:159–67.Search in Google Scholar

[2] Berg CJ, Mackay AP, Qin C, Callaghan WM. Overview of maternal morbidity during hospitalization for labor and delivery in the United States: 1993–1997 and 2001–2005. Obstet Gynecol. 2009;113:1075–81.10.1097/AOG.0b013e3181a09fc0Search in Google Scholar

[3] Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33:130–7.10.1053/j.semperi.2009.02.010Search in Google Scholar

[4] Espinoza J, Romero R, Nien JK, Gomez R, Kusanovic JP, Goncalves LF, et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol. 2007;196:326.e1–13.10.1016/j.ajog.2006.11.002Search in Google Scholar

[5] Haddad B, Deis S, Goffinet F, Paniel B, Cabrol D, Sibai BM. Maternal and perinatal outcomes during expectant management of 239 severe preeclamptic women between 24 and 33 weeks’ gestation. Am J Obstet Gynecol. 2004;190:1590–7.10.1016/j.ajog.2004.03.050Search in Google Scholar

[6] Jank A, Schaarschmidt W, Stepan H. Effect of steroids on angiogenic factors in pregnant women with HELLP syndrome. J Perinat Med. 2011;39:611–3.10.1515/jpm.2011.068Search in Google Scholar

[7] Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367:1066–74.10.1016/S0140-6736(06)68397-9Search in Google Scholar

[8] Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med. 2009;22:1021–38.10.3109/14767050902994754Search in Google Scholar PubMed PubMed Central

[9] Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992–1005.10.1056/NEJMoa055352Search in Google Scholar PubMed

[10] Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–83.10.1056/NEJMoa031884Search in Google Scholar PubMed

[11] Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649–58.10.1172/JCI17189Search in Google Scholar PubMed PubMed Central

[12] Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol. 2007;197:244.e241–8.10.1016/j.ajog.2007.06.030Search in Google Scholar PubMed

[13] Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy. Am J Obstet Gynecol. 2000;183:S1–22.10.1067/mob.2000.107928Search in Google Scholar

[14] Robinson CJ, Johnson DD, Chang EY, Armstrong DM, Wang W. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol. 2006;195:255–9.10.1016/j.ajog.2005.12.049Search in Google Scholar PubMed

[15] Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 2008;21:9–23.10.1080/14767050701830480Search in Google Scholar PubMed PubMed Central

[16] Staff AC, Braekke K, Harsem NK, Lyberg T, Holthe MR. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol. 2005;122:33–9.10.1016/j.ejogrb.2004.11.015Search in Google Scholar PubMed

[17] Stepan H, Unversucht A, Wessel N, Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension. 2007;49:818–24.10.1161/01.HYP.0000258404.21552.a3Search in Google Scholar PubMed

[18] Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, Schaarschmidt W, et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation. 2011;124:94050.10.1161/CIRCULATIONAHA.111.034793Search in Google Scholar PubMed

[19] Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol. 2010;202:161.e1–11.10.1016/j.ajog.2009.09.016Search in Google Scholar PubMed

[20] Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol. 2012;206:58.e1–8.10.1016/j.ajog.2011.07.037Search in Google Scholar PubMed

[21] Young B, Levine RJ, Salahuddin S, Qian C, Lim KH, Karumanchi SA, et al. The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonatal Med. 2010;23:366–70.10.3109/14767050903184207Search in Google Scholar

The authors stated that there are no conflicts of interest regarding the publication of this article.

Received: 2012-10-19
Accepted: 2013-2-25
Published Online: 2013-04-11
Published in Print: 2013-09-01

©2013 by Walter de Gruyter Berlin Boston

Downloaded on 29.3.2024 from https://www.degruyter.com/document/doi/10.1515/jpm-2012-0248/html
Scroll to top button